Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will participate in two June investor conferences, featuring executive fireside chats and webcast access for investors.

The company develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders, with several FDA-approved therapies and multiple mid- to late-stage clinical programs.

News Market Reaction – NBIX

+0.06%

+0.06% Session close to close

In the May 27 session, NBIX gained 0.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

• William Blair 46^th Annual Growth Stock Conference. Fireside chat on Tuesday, June 2, 2026 at 10:40 AM CT (11:40 AM ET) in Chicago
  
  
• Goldman Sachs 47^th Annual Global Healthcare Conference 2026. Fireside chat on Tuesday, June 9, 2026 at 9:20 AM ET in Miami

The webcasts can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)  

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june-302782255.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the William Blair 46th Annual Growth Stock Conference?

Neurocrine Biosciences will present a fireside chat on Tuesday, June 2, 2026, at 10:40 AM CT (11:40 AM ET) in Chicago. According to Neurocrine Biosciences, the session will also be available via live webcast on its investor website.

What are the details of Neurocrine Biosciences (NBIX) appearance at the Goldman Sachs 47th Annual Global Healthcare Conference 2026?

Neurocrine Biosciences will host a fireside chat on Tuesday, June 9, 2026, at 9:20 AM ET in Miami. According to Neurocrine Biosciences, investors can access the event through a webcast on the company’s investor relations webpage.

How can investors access the Neurocrine Biosciences (NBIX) June 2026 conference webcasts?

Investors can access the conference webcasts through the Investors section of neurocrine.com. According to Neurocrine Biosciences, replay versions will be available about one hour after each event and archived on the website for approximately one month.

What does Neurocrine Biosciences (NBIX) focus on in its biopharmaceutical portfolio?

Neurocrine Biosciences focuses on treatments for under-addressed neurological, psychiatric, endocrine and immunological disorders. According to Neurocrine Biosciences, its portfolio includes FDA-approved therapies for tardive dyskinesia, Huntington’s chorea, congenital adrenal hyperplasia, Prader-Willi hyperphagia, endometriosis and uterine fibroids, plus multiple mid- to late-stage pipeline programs.

Which FDA-approved treatments does Neurocrine Biosciences (NBIX) highlight in its June 2026 conference announcement?

Neurocrine Biosciences highlights FDA-approved treatments for tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, Prader-Willi hyperphagia, endometriosis and uterine fibroids. According to Neurocrine Biosciences, the endometriosis and uterine fibroids therapies are developed in collaboration with AbbVie.

What investor information will likely be discussed by Neurocrine Biosciences (NBIX) at the June 2026 conferences?

The conferences will feature executive fireside chats that may cover the company’s treatments and pipeline across neurological, psychiatric, endocrine and immunological disorders. According to Neurocrine Biosciences, these meetings support ongoing engagement with investors through live and archived webcasts.